Coronary Artery Bypass Grafting in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES (INDICATIONS):

• Significant left main coronary artery stenosis (≥50%) regardless of symptom severity

• Three-vessel CAD with or without proximal LAD involvement, especially with SYNTAX Score >22

• Two-vessel or three-vessel CAD with diabetes mellitus (CABG demonstrates superior 5-year outcomes over PCI in diabetic multivessel disease — FREEDOM trial data)

• Reduced left ventricular ejection fraction (LVEF <35–40%) with viable myocardium confirmed on imaging

• Failed or unsuitable anatomy for PCI (heavily calcified vessels, bifurcation lesions not amenable to stenting, chronic total occlusions)

• Recurrent in-stent restenosis or prior failed PCI

• Combined valvular and coronary disease requiring concomitant surgical correction

• Acute coronary syndrome with cardiogenic shock or mechanical complications not responsive to percutaneous intervention

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Coronary angiography (gold standard; CT coronary angiography as non-invasive alternative in select patients)

• 2D Echocardiography (ECHO) — assessment of LVEF, wall motion abnormalities, valve function, and pericardial status

• Myocardial viability assessment: Nuclear stress test (Tc-99m SPECT), Cardiac MRI with late gadolinium enhancement, or PET-CT (FDG-PET for hibernating myocardium in low-EF patients)

• Pulmonary function tests (PFTs) — critical for patients with concurrent COPD

• Carotid Doppler ultrasound — to rule out significant carotid stenosis before placing on cardiopulmonary bypass

• Lower limb venous Doppler — pre-harvest assessment of saphenous vein quality

• Complete blood panel: CBC, coagulation profile (PT/INR, aPTT), renal function, HbA1c, lipid panel, thyroid function

• Chest X-ray and 12-lead ECG

• HLA typing and infectious serology (HIV, HBsAg, HCV, VDRL) as per institutional protocol

• CONTRAINDICATIONS AND HIGH-RISK FACTORS:

• Severely depressed LVEF (<20%) without demonstrated myocardial viability on PET-CT or cardiac MRI

• End-stage renal disease on dialysis (significantly elevated operative risk; surgery may still proceed at specialized centers with careful planning)

• Severe, irreversible pulmonary hypertension

• Active systemic infection or bacteremia

• Severely calcified (porcelain) aorta — markedly increases embolic risk with aortic cross-clamping; may require off-pump or alternative cannulation strategies

• Uncorrectable bleeding diathesis or inability to tolerate anticoagulation

• EuroSCORE II or STS predicted mortality >10–15% in elective settings (relative contraindication; Heart Team consensus required)

SURGICAL TECHNIQUES FOR CABG:

1. CONVENTIONAL ON-PUMP CABG (Standard Approach):

The most widely performed technique, utilizing cardiopulmonary bypass (CPB) with a heart-lung machine and cardioplegic cardiac arrest (cold blood or del Nido cardioplegia). This provides a bloodless, motionless operative field optimal for complex multi-vessel anastomoses. The sternum is accessed via a median sternotomy. LIMA-to-LAD anastomosis — the cornerstone of durable CABG — achieves 10-year patency rates exceeding 90%, compared to approximately 60–70% for saphenous vein grafts. Total arterial revascularization (LIMA + RIMA + radial artery) is preferred in younger patients (<65 years) to maximize long-term graft patency.

2. OFF-PUMP CABG (OPCAB — Beating Heart Surgery):

Performed on a beating heart using tissue stabilizer devices (e.g., Medtronic Octopus, Guidant Ultima) without CPB. OPCAB eliminates CPB-related systemic inflammatory response, reduces risk of neurological complications (postoperative cognitive dysfunction, stroke), and is particularly advantageous in patients with severely calcified aortas, renal insufficiency, or advanced age. Multiple studies (ROOBY, CORONARY trials) demonstrate equivalence in mortality with potential benefit in high-risk subgroups. Requires a highly experienced surgical team for complex multi-vessel cases.

3. MINIMALLY INVASIVE DIRECT CORONARY ARTERY BYPASS (MIDCAB):

Accesses the heart via a small left anterior thoracotomy (5–8 cm incision) without sternotomy. Typically used for isolated LIMA-to-LAD bypass in patients with single-vessel LAD disease or as a hybrid strategy combined with PCI for non-LAD vessels. Benefits include shorter hospital stay, faster recovery, reduced blood loss, and superior cosmetic outcome. Not suitable for complex multi-vessel disease.

4. TOTALLY ENDOSCOPIC / ROBOTIC-ASSISTED CABG (TECAB):

Utilizes robotic surgical platforms (da Vinci Surgical System) to perform completely endoscopic coronary anastomoses through port-site incisions of 8–12 mm. Achieves LIMA-to-LAD anastomosis with precision comparable to open surgery, with minimal tissue trauma and significantly accelerated recovery. Available at select high-volume centers in India (Narayana Health, Apollo Hospitals) and the UAE (Cleveland Clinic Abu Dhabi). Most appropriate for single or double-vessel disease in non-obese patients with favorable anatomy.

5. HYBRID CORONARY REVASCULARIZATION (HCR):

A combined strategy where the cardiac surgeon performs a MIDCAB or robotic LIMA-to-LAD bypass (providing the most durable conduit to the most critical vessel), followed by PCI with drug-eluting stents (DES) for the remaining non-LAD lesions. This approach maximizes durability of LAD revascularization while minimizing surgical trauma for additional vessels. Particularly suited for patients with complex anatomy not amenable to full surgical revascularization or those wishing to avoid full sternotomy.

6. CONDUIT SELECTION STRATEGY:

• LIMA-to-LAD: Gold standard; mandatory in virtually all CABG cases in appropriate anatomy

• Bilateral Internal Mammary Arteries (BIMA): Superior long-term survival vs. single IMA; used cautiously in diabetics due to increased sternal wound infection risk (mitigated by skeletonization harvesting technique)

• Radial Artery: Excellent 10-year patency (>80%) when bypassing vessels with ≥70% stenosis; requires pre-op Allen test or Doppler to confirm ulnar artery adequacy

• Saphenous Vein Graft (SVG): Widely available; inferior long-term patency; endoscopic vein harvesting (EVH) reduces leg wound complications

7. CONCOMITANT PROCEDURES:

CABG is frequently combined with mitral valve repair/replacement, surgical ventricular restoration (SVR/Dor procedure) for large anterior aneurysms, ablation procedures for concurrent atrial fibrillation (Cox-Maze IV), or septal myectomy in hypertrophic obstructive cardiomyopathy.

PRE-OPERATIVE PHASE (Days -7 to -1):

• Day -7 to -5: Remote consultation with GAF Healthcare's cardiac surgery team. Upload and review of all existing investigations (coronary angiography films, echo reports, prior catheterization data). EuroSCORE II and SYNTAX Score calculated. Surgical approach and conduit strategy discussed with the patient and family.

• Day -5 to -3: Arrival in India or UAE. Airport transfer arranged by GAF Healthcare. Admission to partner hospital or pre-admission outpatient evaluation. Repeat or supplementary diagnostics performed if required (carotid Doppler, viability study, PFTs). Anesthesia pre-assessment and optimization of comorbidities (glycemic control targeting HbA1c <7.5%, antihypertensives, discontinuation of anticoagulants per protocol).

• Day -2 to -1: Pre-operative optimization completed. Informed consent obtained with language-specific interpreter provided by GAF Healthcare. Bowel preparation, skin preparation, and sternal antiseptic protocol initiated. Chest physiotherapy teaching (IS — Incentive Spirometry) commenced. Patient NPO (nil per os) from midnight.

PROCEDURE DAY (Day 0):

• General anesthesia induced; intraoperative transesophageal echocardiography (TEE) used for real-time cardiac function monitoring.

• Conduit harvesting performed simultaneously by assisting surgical team (endoscopic vein harvest from leg; skeletonized LIMA/RIMA takedown).

• Median sternotomy performed; systemic heparinization for CPB or OPCAB stabilization device deployed.

• Distal anastomoses completed first (typically LIMA-to-LAD, then sequential or individual grafts to other vessels), followed by proximal anastomoses to aorta.

• Protamine administered to reverse heparin; hemostasis confirmed; sternal closure with stainless steel wires; layered soft tissue closure.

• Procedure duration: 3–5 hours for standard 3-vessel CABG; 5–7 hours for complex cases or concomitant valve surgery.

• Patient transferred to Cardiac ICU (CICU) on mechanical ventilation.

POST-OPERATIVE PHASE — HOSPITAL (Days 1–9):

• Day 1 (CICU): Extubation targeted within 6–8 hours (fast-track anesthesia protocol). Hemodynamic monitoring via arterial line, central venous catheter, and pulmonary artery catheter if required. Chest drain output monitored. Initiation of aspirin (325 mg loading dose for SVG patency).

• Day 2–3: Chest drains and urinary catheter removed. Patient mobilized to sitting and standing. Cardiac rehabilitation Phase I begins: deep breathing exercises, incentive spirometry, assisted ambulation.

• Day 4–5: Transfer to step-down cardiac ward. Ambulation with physiotherapist to 100–200 meters. Oral pharmacotherapy consolidated: aspirin, high-intensity statin (rosuvastatin 40 mg or atorvastatin 80 mg), beta-blocker (metoprolol succinate), ACE inhibitor/ARB, and anticoagulation if indicated (post-AF or low-EF).

• Day 6–7: Wound inspection and dressing change. Sternal stability confirmed. Dietary counseling and cardiac diet education. Blood sugar optimization in diabetic patients.

• Day 8–9: Pre-discharge echocardiography. Discharge blood panel (CBC, renal function, INR). Discharge medications prescribed; patient and family educated on sternal precautions, activity restrictions, warning signs (fever, wound dehiscence, palpitations, chest pain).

• Discharge: Day 8–10 post-operatively for uncomplicated cases.

POST-OPERATIVE PHASE — OUTPATIENT IN-COUNTRY (Weeks 2–6):

• Week 2–3: Follow-up wound clinic visit. Staple/suture removal. Chest X-ray to assess pleural effusion or pneumothorax resolution. ECG and basic blood work. Activity progression: walking 20–30 minutes daily at a comfortable pace.

• Week 3–4: Cardiology outpatient review. Echocardiography if LVEF was depressed pre-operatively. Neurological assessment if cognitive concerns. Introduction of structured Phase II cardiac rehabilitation.

• Week 4–6: Fit-to-fly assessment. International flight cleared only when: (a) sternal wound is fully healed with no signs of infection; (b) no symptomatic pleural effusion; (c) no significant arrhythmia; (d) patient can walk 200 meters without dyspnea or angina; (e) no requirement for IV medications. Long-haul flights (>6 hours) require additional precautions: compression stockings, aspirin, and periodic ambulation in the cabin.

RECOVERY MILESTONES AT HOME (Weeks 6–12):

• Week 6: Light household activities resumed; driving permitted when patient can perform emergency braking without sternal pain (typically 6–8 weeks).

• Week 8–10: Return to sedentary/desk work; Phase III outpatient cardiac rehabilitation commenced with cardiologist in home country.

• Week 12: Most patients report significant improvement in exercise tolerance and quality of life. Repeat stress test or functional imaging at 3 months in selected cases.

• Month 3–6: Return to moderate physical activity; sexual activity generally safe from week 6–8 (sternal precautions apply).

• Month 12: Annual cardiology follow-up with lipid panel, renal function, HbA1c, and stress imaging if symptomatic.